Review
Therapeutic recombinant proteins: trends in US approvals 1982 to 2002
Affiliations
- PMID: 12772503
Item in Clipboard
Review
Therapeutic recombinant proteins: trends in US approvals 1982 to 2002
Curr Opin Mol Ther.
2003 Apr.
Abstract
Recombinant proteins have become an important class of therapeutics since the first product was approved for marketing in the US in 1982. To determine trends in the clinical development and approval processes for therapeutic recombinant proteins, data for 270 products that entered clinical study in the period 1980 to 2002 were collected and analyzed. Mean clinical and approval phase lengths for 54 US-approved products stratified by time period, therapeutic indication, protein type, review rating and FDA review center are compared. Approval success rates, calculated using three methods that differ only in the definition of success, and the variation of approval success rates over five time periods are presented.
Similar articles
-
Therapeutic monoclonal antibodies: trends in development and approval in the US.Curr Opin Mol Ther. 2002 Apr;4(2):110-8. Curr Opin Mol Ther. 2002. PMID: 12044031 Review.
-
Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.Clin Ther. 2013 Jun;35(6):808-18. doi: 10.1016/j.clinthera.2013.04.004. Epub 2013 May 28. Clin Ther. 2013. PMID: 23726388
-
Clinical development of therapeutic recombinant proteins.Biotechniques. 2003 Jul;35(1):176-8, 180, 182-5. doi: 10.2144/03351dd01. Biotechniques. 2003. PMID: 12866419
-
Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.J Natl Cancer Inst. 2010 Feb 24;102(4):230-43. doi: 10.1093/jnci/djp515. Epub 2010 Jan 29. J Natl Cancer Inst. 2010. PMID: 20118413 Review.
-
Recombinant protein therapeutics--success rates, market trends and values to 2010.Nat Biotechnol. 2004 Dec;22(12):1513-9. doi: 10.1038/nbt1204-1513. Nat Biotechnol. 2004. PMID: 15583654 No abstract available.
Cited by
-
The Diphtheria Toxin Translocation Domain Impairs Receptor Selectivity in Cancer Cell-Targeted Protein Nanoparticles.Pharmaceutics. 2022 Nov 29;14(12):2644. doi: 10.3390/pharmaceutics14122644. Pharmaceutics. 2022. PMID: 36559138 Free PMC article.
-
Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies.Adv Sci (Weinh). 2019 Jul 24;6(18):1900849. doi: 10.1002/advs.201900849. eCollection 2019 Sep 18. Adv Sci (Weinh). 2019. PMID: 31559131 Free PMC article.
-
Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization.Pharm Res. 2006 Sep;23(9):2116-21. doi: 10.1007/s11095-006-9059-5. Epub 2006 Aug 9. Pharm Res. 2006. PMID: 16952003